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A new validated high performance liquid chromatographic (HPLC) method with 
rapid analysis time and high efficiency, for the analysis of erythromycin, 
azithromycin and spiramycin, under isocratic conditions with ODB RP18 as a 
stationary phase is described. Using an eluent composed of acetonitrile –2-methyl-
2-propanol  –hydrogenphosphate buffer, pH 6.5, with 1.5% triethylamine (33:7: up 
to 100, v/v/v), delivered at a flow-rate of 1.0 mL min-1. Ultra Violet (UV) detection 
is performed at 210 nm. The selectivity is satisfactory enough and no problematic 
interfering peaks are observed. The procedure is quantitatively characterized and 
repeatability, linearity, detection and quantification limits are very satisfactory. 
The method is applied successfully for the assay of the studied drugs in 
pharmaceutical dosage forms as tablets and powder for oral suspension. Recovery 
experiments revealed recovery of 97.13–100.28%. 
  Open Access 2016 – University of Huddersfield Press 
INTRODUCTION 
Macrolides are an important class of antimicrobial 
compounds. Of the macrolide antibiotics currently in 
clinical use, erythromycin, azithromycin and 
spiramycin are the most widely prescribed, against 
infectious diseases caused by a number of different 
microorganisms (Elks and Ganellin, 1991). 
Erythromycin, azithromycin and spiramycin are 
complex carbohydrates. The common selection of 
these substances which have molecular mass's in the 
range of 689 to 842, is macrocyclic lactone ring 
containing 14, 15 or 16 atoms with neutral and/or 
amino sugars linked via glycosidic bonds (Omura, 
1984). The chemical structures of erythromycin 
(ERY), azithromycin (AZI) and spiramycin (SPI) are 
depicted in Figure 1.  
Analysis of macrolide antibiotics has been performed 
by paper chromatography, thin–layer 
chromatography as well as gas and liquid 
chromatography (LC) among these methods, LC is 
the most popular technique used for the analysis of 
macrolides (Lahane et al., 2014; Kanfer et al., 1998).  
Several HPLC methods for the individual analysis of 
macrolides in a variety of matrices including raw 
material, pharmaceutical dosage forms, biological 
fluids and various tissues have been reported 
(Kanfer et al., 1998; Nasr and Tscchappler, 1996; 
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Kauss et al., 2012; Cao et al., 2013), merely for 
erythromycin   and occasionally for the other 
macrolides. Unfortunately, most official methods for 
the analysis of macrolides are mainly antimicrobial 
assays (Mahmoudi et al., 2015; British 
Pharmacopoeia, 1998; Official Methods for Residual 
Substances in Livestock Products, 1994), which they 
suffer from many disadvantages as the long 
incubation periods and the lack of sensitivity. Other 
reported HPLC methods, including electrochemical 
detection (Duthu, 1984), fluorescence detection by 
pre-column derivatization (Bahrami et al., 2005) and 
liquid chromatography–mass spectrometry or LC–
MS/MS (Gonzalez de la Huebra et al., 2004; Shen et 
al., 2010) have been used for the individual 
quantitative determination of ERY, AZI and SPI. 
These methods were time-consuming, tedious, and 
dedicated to sophisticated and expensive analytical 
instruments. Many LC methods have been applied to 
multiresidue analysis of macrolides in biological 
samples (Gonzalez de la Huebra et al., 2007; Dubois 
et al., 2001), and no reversed–phase LC methods have 
been reported for the simultaneous determination of 
the three macrolides in routine pharmaceutical 
dosage forms. 
In this manuscript, a novel validated, rapid, precise 
and robust HPLC method by using response peak-
height methodology and ODB stationary phase was 
described for the analysis and quantitative 
determination of erythromycin, azithromycin and 
spiramycin in raw material and pharmaceutical 
dosage forms. In addition, simultaneous separation 
was also applied to support the economical 
suitability of this method. 
2. MATERIALS AND METHODS 
2.1. Apparatus  
LC experiments were performed using a LC–
10ATVP pump (Shimadzu, Japan) equipped with an 
injector model Rheodyne (C.C, U.S.A) and a 20µL 
loop, a SPD –10AVP UV–vis detector (Shimadzu, 
Japan) set at 210 nm. The column was immersed in a 
water–bath, heated by a memert D–91126 thermostat 
(FRG, Germany). Separation was achieved with ODB 
RP18 column, 250 mm × 4.6 mm, packed with silica 





















Fig.1. Chemical structures of [A] erythromycin, [B} 
azithromycin and [C] spiramycin. 
2.2. Materials and reagents  
Pharmacopeial standards of erythromycin and 
spiramycin were purchased from Sigma (Steiheim, 
Germany), and working standard of azithromycin 
was kindly provided from SAIDAL–GROUPE 
(Saidal, Algeria), while pharmaceuticals containing 
these macrolide antibiotics were obtained 
commercially. Erybesan® film-coated tablets 
(Sandoz, Algeria): labelled to contain erythromycin 
stearate as 500 mg/tablet; Azimycine® powder for 
oral suspension (Saidal, Algeria): labelled to contain 
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(Saidal, Algeria): labelled to contain spiramycin as 
1.5 MIU/tablet (equivalent of 1.0 IU is 0.3µg).   
Dipotassium hydrogenphosphate, 2-methyl-2-
propanol, acetonitrile (ACN), triethylamine and 
absolute ethanol were of analytical–reagent grade 
from SIGMA–ALDRICH (Steiheim, Germany). 
Methanol was of chemical grade from the same 
source. The following mobile phase was finally used: 
acetonitrile–2-methyl-2-propanol–0.025M potassium 
phosphate buffer (pH 6.5) (33: 7: up to 100, v/v/v), 
the flow–rate was 1.0 mL min-1. The phosphate buffer 
solution was filtered through a Millipore GS 0.22 µm 
filter (Milford, MA, USA). Deionized and double-
distilled water was used throughout all experiments.  
2.3. Preparation of Standard Solutions  
Stock standard solutions of ERY and AZI were 
prepared by dissolving 400 mg of each compound in 
100 mL of 0.025 M dipotassium hydrogen phosphate 
(pH 6.5)–acetonitrile (7:3, v/v), while a weighed 
quantity of 100 mg of SPI was dissolved in 100 mL of 
water–acetonitrile (7:3, v/v). The standard solutions 
were kept at 4°C in amber glass vessels. From each 
standard solution a series of dilution was prepared 
quantitatively in appropriate solvent to obtain 
standard solutions having concentration ranges of 
linearity. The solutions were prepared freshly every 
day and used as working standards.  
2.4. Sample Preparation  
2.4.1. Erybesan® Tablets  
The sample preparation was done as follows based 
on a previous paper (Khashaba, 2002).  Ten tablets 
were weighed and finely powdered.  A weighed 
portion equivalent to the weight of one tablet was 
transferred to a 100 mL volumetric flask, sonicated 
for 5 min with about 10 mL phosphate buffer(pH 
6.5)–acetonitrile (7:3, v/v) then the solution was 
diluted to volume with the same solvent. The 
mixture was mixed well, allowed any insoluble 
matter to settle then filtered through a Millipore GS 
0.22 µm filter. A measured volume of the filtrate was 
diluted quantitatively with the same solvent to yield 
a sample solution having a working concentration 
assumed to be 4.0 mg mL−1. This sample was 
evaluated in triplicate. This procedure was 
performed two times.  
2.4.2. Azimycine® Powder for Oral Suspension  
An amount of powder equivalent to 100 mg of 
azithromycin was transferred to 25 mL volumetric 
flask with 15 mL absolute ethanol and shaken for 20 
min, followed by marking up to volume with the 
same solvent. The procedure was then completed as 
in Section 2.4.1 to yield a sample solution having a 
concentration assumed to be 4.0 mg mL−1 of 
azithromycin. This sample was evaluated in 
triplicate. This procedure was performed two times. 
2.4.1. Rovamycin® Tablets 
 An amount equivalent to 450 mg of spiramycin was 
transferred to 200 mL volumetric flask with 50 mL 
water–acetonitrile (7:3, v/v) and shaken for 20 min, 
followed by marking up to volume with the same 
solvent. After filtration, from this solution a series of 
dilution was prepared quantitatively in double 
distilled water to give a final concentration of 1.0 mg 
mL−1 of SPI. This sample was evaluated in triplicate. 
This procedure was performed two times. 
2.5. Method Validation  
The method was validated by determination of 
linearity, sensitivity, precision, accuracy and 
specificity (US Pharmacopoeia, 2000; Validation on 
analytical procedures, 1996). Each day, a quantity of 
about 25 mg of macrolide was weighed and 
dissolved in appropriate solvent. Independent 
dilutions were then undertaken to cover our 
analytical dynamic range.  
2.5.1. Linearity   
In order to assess the validity of the assay seven 
doses of the reference substance were used. 
Standards at concentration ranges of: 0.002–4.8, 
0.004–4.8 and 0.0003–1.2 mg mL−1 for erythromycin, 
azithromycin and spiramycin, respectively, were 
prepared from their stock standard solutions. A 20 
µL volume of these solutions was injected into the 
column. The calculation of regression line by the 
method of least squares was employed. 
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2.5.2. Precision and Accuracy 
Precision and accuracy were assessed by performing 
replicate analysis of quality control samples. Three 
different concentration solutions within calibration 
range (80, 100 and 120%) were prepared and 
analyzed with calibration curve to determine intra–
day (5 replicates per concentration) and inter–day (5 
replicates per concentration over 1–3 days) 
variability. 
2.5.3. Interference Studies and Stability  
The previous tests proposed with the samples in 
comparison to the standard should detect excipients 
and/or probable impurities and in this case the 
contents would propositional to the peak-height. The 
Student's t-test was performed to compare the 
macrolide standard and sample values. 
Different aliquots of standard preparation and 
solutions were treated with 1.0 M hydrochloride, 1.0 
M sodium hydroxide, hydrogen peroxide (3.0%) and 
exposed to natural light and UV lamp during 24 h, 
neutralized and suspended in mobile phase were 
then analyzed by the procedure described above in 
order to study method selectivity. 
Drug stability of macrolides were evaluated at low 
and high concentrations of standards after short and 
long times of storage at room temperature for 4 and 
8 h, at 4°C for one, two and three weeks. Stability 
studies were estimated by comparing the detector 
response of tested solutions (after storage) with that 
of freshly prepared ones (measured at zero time).  
In the case of the simultaneous study sample, several 
volumes of ERY, AZI and SPI working samples were 
added to 10 mL flask. After slightly mixing, the 
obtained homogenized mixture was filtered. Then, a 
20 µL of the filtrate solution was injected into the 
HPLC system.  
3. RESULTS AND DISCUSSION 
3.1. Method Development   
Macrolides are basic compounds having one or 
several amino sugars in their molecule and strongly 
affected by residual silanols groups remaining in the 
column packing material. So, the choice of adequate 
conditions for a HPLC separation is governed by the 
ionizable group, i.e. amino sugar, of the three 
macrolides (Edder et al., 2002). Previous results, 
obtained for troleandomycin and erythromycin, 
indicated that a neutral mobile phase pH favoured 
the separation of macrolides on X Terra RP18 
(Chepkwony et al., 2001a, 2001b, 2001c). Therefore, 
mobile phases containing different amounts of 
acetonitrile, as organic modifier (x%, v/v), 0.2 M 
phosphate buffer pH 7.0 (5%, v/v) and water (95–x 
%, v/v) were used as starting conditions for method 
development. In order to improve the separation and 
peak symmetry, the chromatographic variable 
acetonitrile (%), buffer pH, buffer concentration and 
temperature were investigated. 
Fig.2. Influence of the concentration of acetonitrile (ACN) in the 
mobile phase on the capacity factors (K') of ERY, AZI and SPI. 
Mobile phase : acetonitrile- 0.01 M potassium phosphate buffer 
(pH 7) (x: up to 100,  v/v);  stationary phase : ODB RP18 5µm 
(250×4.6 mm I.D.) ; flow-rate : 1.0 ml min-1 ; temperature : 
ambient  ; detection : UV at 215 nm .   
Several organic modifiers were investigated. The 
influence of the concentration of acetonitrile 
(CH3CN) in the mobile phase on the selectivity is 
shown in Figure 2. The capacity factors decreased 
rapidly with increasing amounts of acetonitrile. The 
separation of ERY–AZI remained satisfactory over 
the range 31% to 46%. The separation SPI–ERY was 
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such as 2-methyl-2-propanol, tetrahy-drofuran or 
methanol was necessary. Addition of some 2-methyl-
2-propanol as a second organic modifier reduced the 
analysis time but did not influence  the selectivity, so 
the amount of 2-methyl-2-propanol could be 
decreased, which improved the separation SPI–ERY. 
Amounts of 33% v/v of acetonitrile, and 7 % v/v of 
2-methyl-2-propanol were chosen to be as optimal in 
terms of selectivity and analysis time. 
Fig.3. Influence of mobile phase pH on the capacity factors (K') 
of ERY, AZI and SPI. Mobile phase: CH3CN - 2-methyl-2-
propanol- 0.01 M potassium phosphate buffer (pH x) (33:7: up to 
100, v/v/v). See fig.2 for experimental conditions.   
Mobile phase pH is an important parameter that can 
be manipulated to optimise selectivity in HPLC as it 
enhances mobility differences between the solutes 
and the stationary phase (KLalloo et al., 1997). The 
influence of the pH on the selectivity was 
investigated between 5.5 to 7.5 (Figure 3). Below pH 
6.5 the capacity factors decreased rapidly with loss of 
selectivity. At pH 7.0 the separation ERY–AZI was 
good, but SPI was no longer separated from ERY and 
the peak corresponding to ERY was slightly 
distorted, because of co-elution with SPI. At pH 
above 7.0 the separation was poorer, and column 
efficiencies decreased by 40% relative to values 
below pH 7.0. The results indicated that in the pH 
range 6.0 to 7.0, small pH changes did not 
significantly affect the separation and therefore pH 
6.5 was chosen for further work. The effect of the 
concentration of potassium phosphate buffer (pH 
6.5) was negligible in range 0.01–0.04 M. An 
increasing in the concentration of potassium 
phosphate buffer decreases the capacity factors. A 
possible explanation is that, due to the formation of 
ion pair with macrolide. 0.025 M buffer concentration 
was therefore chosen as the best compromise because 
it afforded optimal separation for all the components 
with better peak symmetry. 
It is known that temperature is a useful parameter 
that sometimes provides profound changes in 
selectivity. Because column temperature has proved 
to be useful variable in reversed–phase LC 
separations (Dolan, 2000). Therefore, the influence of 
the column temperature was examined over the 
range: 25–50 °C. It was observed that an increase in 
temperature led to an increase in retention times. 
This chromatographic behaviour has previously 
been observed with macrolides (Dolan, 2000; Cachet 
et al., 1987). It is probable that the hydrophobicity of 
these antibiotics increases with temperature, because 
of poorer solvation, and this leads to stronger 
interaction with the apolar stationary phase. This 
phenomenon correlates well with the lower 
solubility of these substances in aqueous solutions at 
higher temperatures (Chepkwony et al., 2001d).  
At 25°C elution was rapid with complete loss of 
selectivity. Increasing the temperature improved the 
selectivity but also led to longer retention times. 
Cachet et al. also previously reported this 
observation (Cachet et al., 1987). A temperature of 
30°C was chosen as optimum for the separation. This 
temperature is very important for baseline–
resolution, better peak symmetry and shorter 
retention times. Triethylamine was used as a 
shielding agent, which usually improves peak shape 
in compounds with amino groups. 
The macrolides were dissolved in appropriate 
solvent and their UV spectra were measured.  The 
UV absorption maxima were in the vicinity of 215 nm 
for ERY,   210 nm for AZI and 230 nm for SPI, and 210 
nm was chosen for the simultaneous detection. The 
final composition of the mobile phase chosen is 
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potassium phosphate buffer (pH 6.5), with 1.5% 
triethylamine (33: 7: up to 100, v/v/v). 
3.2. Assay Validation 
3.2.1. Linear Working Range 
The linearity of method was determined by injection 
of various standard concentrations. Linear plots with 
good correlation coefficients (r) (more than 0.999) 
were obtained in the concentration ranges of 0.002–
4.8, 0.004–4.8 and 0.0003–1.2 mg mL−1 for the ERY, 
AZT and SPI, respectively. Typically, the regression 
equation for the calibration curve was found to be y 
= 28551.54 x + 899.31 (r=0.9998) for erythromycin, y 
= 44279.89 x + 20.87 (r=0.9995) for azithromycin and 
y = 503657.84 x + 5557.96 (r=0.9998) for spiramycin, 
where x are peak–height values and y the 
concentration values in mg mL-1. The r values were 
found to be acceptable and significant with 
confidence intervals at P=0.05.  
3.2.2. Limit of Detection and Limit of Quantification 
Limit of detection (LOD) and limit of quantitation 
(LOQ) levels are only valuable in analytical methods 
for purity, and they give no important information in 
assay determinations. Nevertheless, to present the 
sensitivity of the developed method, the minimum 
level at which the investigated compound can be 
reliably detected and quantified was determined 
experimentally. By steadily diluting the samples, for 
an injection of 20 µL, the LOQ with a signal-to-noise 
ratio of 10 was: 0.07% for ERY; 0.05% for SPI and 
0.09% for AZI. The LOD with a signal-to-noise ratio 
of 3 was: 0.02% for ERY and SPI and 0.03% for AZI. 
The chromatogram peaks resembling these 
concentrations were all clearly distinguishable from 
noise peaks. These results indicate the acceptable 
sensitivity of the proposed method comparing to 
some reported HPLC methods (Chepkwony et al., 
2000, 2001d; Yang et al., 2009). 
3.2.3. Method Precision 
The precision is evaluated in terms of repeatability 
(Intra-day precision) and intermediate precision 
(Inter-day precision) expressed by relative standard 
deviations (%RSD). The repeatability RSD values of 
ERY (4.0 mg mL−1), AZI (4.0 mg mL−1) and SPI (1.0 
mg mL−1) were 0.75%, 0.97% and 0.79%, respectively 
(Table 1).  As shown in Table 2, the inter-day 
precisions were less than 1.11%, 1.29% and 1.24% for 
ERY, AZT and SPI, respectively. This level of 
precision is suitable for the routine quality control 
analysis of pharmaceutical dosage forms. 
3.2.4. Accuracy and Recovery 
For pharmaceutical studies, the most widely used 
approach to test accuracy is recovery study. It was 
tested in the same linearity assay. Tables 1 and 2 
summarize the recoveries of drugs.  Results obtained 
indicate good recoveries (mean recoveries greater 
than 90%) and confirm the accuracy of the proposed 
method (%RSD less than 5%). 
3.2.5. Robustness and Ruggedness 
It was examined by evaluating the influence of 
change in mobile phase pH, flow rate, percentage of 
acetonitrile and column oven temperature on the 
method suitability and sensitivity. None of these 
variables significantly affected the relative detection 
intensity (Table 3). This provides an indication of the 
reliability of the proposed method during normal 
usage and so it could be considered robust (US 
Pharmacopoeia, 2000). The ruggedness study was 
done by applying the proposed method to the assay 
of studied macrolides using the same operational 
conditions but using different lab and different 
elapsed time. Results obtained due to lab-to-lab and 
day-to-day variations were found reproducible as % 
RSD did not exceed 4%. 
3.2.6. Specificity and Interference Studies 
The specificity of the method was performed by 
comparison of the chromatograms of drug standard 
and sample solution. The chromatographic 
parameters show a good correlation between the 
results of the two determinations (i.e. ERY, y = 0.988 
x + 0.062; n = 12; r = 0.97). This interference study 
indicated no interfering peak around the studied 
retention times; also baseline showed no significant 
noise. Furthermore, the Student's t-values of ERY, 
AZI and SPI calculated for assay of the commercial 
lots and the recovery study, 1.34, 1.78 and 1.14, 
respectively, are below tabulated values (tn−1, α /2 
from tables= 2.571, for five freedom degrees). These 
results showed that the proposed method can be 
considered specific.
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Table 1. Within–day precision and accuracy of the HPLC analysis of ERY, AZI and SPI   
Drug Theoretical Concentration Experimental Concentrationa Precision (RSD)b Accuracyc 
 (mg mL−1) (x 10-1 mg mL−1) (%) (%) 
ERY 4.80 4.7030 ± 0.43 0.91 97.98 
 4.00 3.9948 ± 0.30 0.75 99.87 
 3.20 3.2038 ± 0.27 0.84 100.12 
AZI 4.80 4.7237 ± 0.36 0.77 98.41 
 4.00 3.9628 ± 0.38 0.97 99.07 
 3.20 3.2090 ± 0.37 1.14 100.28 
SPI 1.20 1.1879 ± 0.12 1.01 98.99 
 1.00 1.0004 ± 0.08 0.79 100.04 
 0.80 0.7905 ± 0.07 0.89 98.81 
a Mean ± SD (n=5) 
b Relative standard deviation  (RSD) =SD/mean×100 
c Accuracy=experimental/theoretical×100 
Table 2. Between–day precision and accuracy of the HPLC analysis of ERY, AZI and SPI 
Drug Theoretical Concentration Experimental Concentrationa Precision (RSD)b Accuracyc 
 (mg mL−1) (x 10-1 mg mL−1) (%) (%) 
ERY 4.80 4.6622 ± 0.51 1.10 97.13 
 4.00 3.9592 ± 0.37 0.93 98.98 
 3.20 3.1747 ± 0.33 1.04 99.21 
AZI 4.80 4.6915 ± 0.60 1.28 97.74 
 4.00 3.9380 ± 0.35 0.89 98.45 
 3.20 3.1782 ± 0.37 1.17 99.32 
SPI 1.20 1.1732 ± 0.19 1.01 97.77 
 1.00 0.9915 ± 0.10 0.99 99.15 
 0.80 0.7835 ± 0.09 1.23 97.94 
a Mean ± SD (n=5) 
b Relative standard deviation  (RSD) =SD/mean×100 
c Accuracy=experimental/theoretical×100. 
Representative chromatograms of erythromycin and 
their degradation products (represented as an 
example of the studied macrolide antibiotics) are 
shown in Figure 4, which shows a good resolution 
with no interference peaks from endogenous 
components at the retention time of ERY, indicating 
the selectivity of measurement. Similar significant 
degradation was obtained for AZI and SPI samples, 
and all degradation products were separated from 
their macrolide peak. Further, to confirm the 
specificity of this analytical method, the 
homogeneity and peak purity of each macrolide peak 
in the samples were estimated based on a 
photodiode-array detector (DAD) scan from 200 to 
400 nm. The obtained peak purity factors were 
comparable with the purity threshold calculated by 
DAD software automatically (i.e. ERY, peak purity 
factor was 994.134 and purity threshold calculated by 
DAD software was 996.781). 
3.2.7. Stability of the assay preparation 
The stability study of ERY, AZI and SPI showed that, 
there are no significant difference in drug 
concentrations upon storage of samples, in 
refrigerator (4 °C) for 21 days,  and at room 
temperature (25°C) for 8 h, with a %RSD remained to 
be less than 5% (< 2.5%; n = 5).  
Over 200 tested solutions were analyzed by this 
method without any significant loss of resolution. No 
change in the column efficiency and back pressure
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Table 3. Results of robustness study 
Factor Level Mean % assay (n = 3)  % R.S.D. of results 
ERY AZI SPI  ERY AZI SPI 
pH of mobile 
 phase 
6.2 99.1 99.4 100.2      0.77 0.98 0.85 
6.4 100.5 99.3 99.8  1.04 1.12 0.98 
Flow rate  
(mL min-1) 
0.9 99.7 98.7 100.7  0.63 1.00 0.79 
1.1 100.3 98.9 99.5  0.91 1.03 1.02 
Column oven 
temperature (◦C) 
25 99.2 99.6 100.2  0.83 0.99 0.89 
35 100.1 98.8 97.0  1.09 1.01 1.18 
% of  
acetonitrile 
31 99.3 98.7 98.3  0.79 1.11 0.78 













Fig.4. Representative chromatograms corresponding to erythromycin (1), as an example of the studied macrolide antibiotics, tested as 
standard (A) and as raw material treated with acid (B), alkali (C), 3.0%-hydrogen peroxide   (D) and, exposed to natural light and UV lamp 
(E). Mobile phase: CH3CN- 2-methyl-2-propanol - 0.025 M potassium phosphate buffer (pH 6.5) (33: 7:  up to 100, v/v/v); stationary phase: 
ODB RP18 5µm (250×4.6 mm I.D.); flow-rate: 1.0 mL min-1; temperature: 30°C; detection: UV at 210nm.  
was also observed over the entire study time, thus 
proving its suitability. 
3.3. Application to analysis of certain commercial lots  
The suggested HPLC method was applied for the 
quantitative determination of ERY, AZI and SPI 
content in marketed products by assaying Erybesan® 
tablets, Azimycine® powder for oral suspension and 
Rovamycin® tablets. The assay showed the drug 
content of these products to be within 
pharmacopoeial limits of label claim. This indicates 
an excellent concordance between experimental and 
nominal values. The results of drug assay in products 
are shown in Table 4. Using this method, a good 
recovery (98.42–99.89%) was obtained without any 
interference from coexisting substances.  
In industry, quantification of ERY, AZI and SPI by 
HPLC method is precise but rather expensive and 
inconvenient. For example, HPLC apparatus is quite 
expensive and a great deal of organic solvents will 
also be used during analysis, and the analysis time is 
also quite long (about 10 min to 1 h per sample), a lot 
of money and time would be cost. On the other hand, 
a large number of reports in the literature (Lahane et 
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al., 2014; Kanfer et al., 1998) have been published for 
the simultaneous analysis of antibiotics in several 
tissues and biological fluids (liver, meat, 
plasma…etc.), by which samples may be screened for 
residual amounts of substances caused by incorrect 
use of these drugs in veterinary practices. However, 
there are few reports described in the literature for 
the simultaneous determination of macrolides in 
dosage forms by HPLC and, to our knowledge, none 
of them includes erythromycin, azithromycin and 
spiramycin. Up to now, no HPLC methods have been 
reported for quantification of these macrolides in 
pharmaceutical dosage forms of the tested local 
markets. Consequently, the developed method was 
applied for the simultaneous separation of these 
analytes. Figure 5 shows a typical chromatogram of 
a mixed solution of the studied macrolides in their 
commercial available dosage forms. As can be seen 
from this figure, the proposed method has the 
advantages of being virtually simple, rapid and 
reliable for quantification practices. 
Fig.5. Chromatogram corresponding to simultaneous analysis of 
SPI (A), ERY (B) and AZI (C). See fig.4 for experimental 
conditions.   
Table 4. Assay of Erythromycin, Azithromycin and Spiramycin in their pharmaceutical formulations 
Descriptiona Label claim Proposed method Reported methode 
Recoveryb (%) RSD (%) Recovery (%) 
1. Erythromcin 
a. Pure ERY 
 99.08 0.78 99.21 
 t-value  1.89   
 F-value  2.71   
b. Erybesan®, tablets 500mg/tablets 98.42 2.42 98.51 
 t-valued  1.52  1.75 
 F-valued  1.28   
2. Azithromycin  
a. Pure AZT 
 98.94 0.89 99.01 
 t-value  1.59   
 F-value  2.17   




99.89 2.19 99.89 
 t-valued  1.98  1.81 
 F-valued  1.17   
3. Spiramycin 
a. Pure SPI 
 100.48 0.81 99.97 
 t-value  1.77   
 F-value  1.31   
b. Rovamycin®, tablets 450mg/tabletsc 98.91 1.98 99.88 
 t-valued  1.42  1.65 
 F-valued  1.21   
a (1) Sandoz, Algiers, Algeria, Lot No.25, Manufactured Jun. 2012;  (2) Saidal, Medea, Algeria, Lot No.136, Manufactured Jan. 2011;  (3) Aventis 
Pharma Saidal, Algiers, Algeria, Lot No. RM001J, Manufactured Aug. 2009.  
b Average of five experiments.    
cLabel claim is 1.5 MIU/tablet  (equivalent of 1.5MIU is 450 mg)  
d Theoretical value at 95% confidence limit and n=5 for F is 6.26 and t is 2.776. 
eRef. (Chepkwony et al., 2001d) for Spiramycin and Ref. (British Pharmacopoeia, 2007) for both Erythromycin and Azithromycin. 
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3.4. Comparison of the proposed method with the 
current assays 
The performance of the proposed method was 
judged by comparing with other reported methods 
(British Pharmacopoeia, 2007; Chepkwony et al., 
2001d).  Then, pharmaceutical formulations of the 
studied drugs were analyzed by the proposed 
method and the current assays, and results indicate 
the high accuracy and precision, as can be seen from 
Table 4. Mean values were obtained with a Student’s 
t- and F-tests at 95% confidence limits for five 
degrees of freedom (Miller and Miller, 1993). The 
results obtained were compared statistically by the 
student’s t-test (for accuracy) and the variance ratio 
F-test (for precision) with those obtained by the 
reference methods on samples of the same batch 
(Table 4). The values of t- and F-tests obtained did not 
exceed the theoretical tabulated value indicating no 
significant difference between the methods 
compared. 
CONCLUSIONS 
The ODB RP18 stationary phase (silice uptisphere, 5 
µm) shows good selectivity toward erythromycin, 
azithromycin and spiramycin. The isocratic method 
presented here is suitable for the quantitative 
determination and to separate ERY, AZI and SPI 
from each other. This new method is simple, linear, 
precise, accurate and rapid. Hence, it can be easily 
adopted for the routine quality control analysis of 
these antibiotics in their pharmaceutical dosage 
forms. 
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